Injectable Drug Recall: Lack of Sterility Assurance at Manufacturing Facility
Pharmacy Innovations is recalling an injectable medication due to lack of sterility assurance caused by insanitary conditions at the manufacturing facility. Affected vials were distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II drug recall with lack of sterility assurance due to insanitary manufacturing conditions. No illnesses or injuries reported, but injectable medications require strict sterile conditions; the facility's insanitary conditions create a high-risk situation without yet-manifested harm.
Plain-English summary
Pharmacy Innovations is recalling Dexpanthenol/Pyridoxine/Hydroxocobalamin 250MG/100MG/1MG/ML injectable medication in 1ML vials distributed nationwide. The recall was initiated due to an FDA inspection that revealed insanitary conditions at the manufacturing facility.
Insanitary facility conditions compromise the assurance that injectable medications have been properly sterilized. Injectable medications must be manufactured under strict sterile conditions, and the insanitary conditions identified by FDA inspection create a risk that these vials may not meet required sterility standards.
Patients and healthcare providers should not use affected vials. Those with questions should contact their healthcare provider or pharmacist. The affected lots are identified by the codes t20221012@64 and t20221114@18.
The recalled product
- Product
- Dexpanthenol/Pyridoxine/Hydroxocobalamin-PF- 250MG/100MG/1MG/ML (1ML vial) Injectable, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Injectable Medication
- Hazard
- lack-of-sterility
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- t20221012@64
- t20221114@18
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27